338 related articles for article (PubMed ID: 27468184)
1. Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.
Matboli M; El-Nakeep S; Hossam N; Habieb A; Azazy AE; Ebrahim AE; Nagy Z; Abdel-Rahman O
World J Gastroenterol; 2016 Jul; 22(26):5896-908. PubMed ID: 27468184
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.
Pellino A; Riello E; Nappo F; Brignola S; Murgioni S; Djaballah SA; Lonardi S; Zagonel V; Rugge M; Loupakis F; Fassan M
World J Gastroenterol; 2019 Oct; 25(38):5773-5788. PubMed ID: 31636471
[TBL] [Abstract][Full Text] [Related]
3. Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.
Hescheler DA; Plum PS; Zander T; Quaas A; Korenkov M; Gassa A; Michel M; Bruns CJ; Alakus H
Gastric Cancer; 2020 Jul; 23(4):627-638. PubMed ID: 32107691
[TBL] [Abstract][Full Text] [Related]
4. Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine.
Wang S; Yuan L
Biosci Trends; 2016 Jul; 10(3):171-80. PubMed ID: 27251446
[TBL] [Abstract][Full Text] [Related]
5. Personalized medicine in gastric cancer: Where are we and where are we going?
Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for gastric adenocarcinoma.
Almhanna K
Adv Pharmacol; 2012; 65():437-70. PubMed ID: 22959034
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the molecular diagnostics of gastric cancer.
Kanda M; Kodera Y
World J Gastroenterol; 2015 Sep; 21(34):9838-52. PubMed ID: 26379391
[TBL] [Abstract][Full Text] [Related]
9. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.
Kim C; Mulder K; Spratlin J
Oncologist; 2014 Oct; 19(10):1046-55. PubMed ID: 25142842
[TBL] [Abstract][Full Text] [Related]
10. Management of advanced gastric cancer.
Price TJ; Shapiro JD; Segelov E; Karapetis CS; Pavlakis N; Van Cutsem E; Shah MA; Kang YK; Tebbutt NC
Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):199-208; quiz 209. PubMed ID: 22375525
[TBL] [Abstract][Full Text] [Related]
11. The low-abundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer.
Bizama C; Benavente F; Salvatierra E; Gutiérrez-Moraga A; Espinoza JA; Fernández EA; Roa I; Mazzolini G; Sagredo EA; Gidekel M; Podhajcer OL
Int J Cancer; 2014 Feb; 134(4):755-64. PubMed ID: 23907728
[TBL] [Abstract][Full Text] [Related]
12. The relevance of gastric cancer biomarkers in prognosis and pre- and post- chemotherapy in clinical practice.
Abbas M; Habib M; Naveed M; Karthik K; Dhama K; Shi M; Dingding C
Biomed Pharmacother; 2017 Nov; 95():1082-1090. PubMed ID: 28922727
[TBL] [Abstract][Full Text] [Related]
13. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
[TBL] [Abstract][Full Text] [Related]
14. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
[TBL] [Abstract][Full Text] [Related]
15. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
Joo MK; Park JJ; Chun HJ
World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
[TBL] [Abstract][Full Text] [Related]
16. [GRP78 expression in gastric cancer and its clinical significance].
Yang L; Yang SY; Ji JM; Cao YF; Ji CF; Ji JF; Xu WW; Wang JH
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):837-42. PubMed ID: 24447482
[TBL] [Abstract][Full Text] [Related]
17. The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression.
Kanda M; Nomoto S; Oya H; Takami H; Shimizu D; Hibino S; Hashimoto R; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2016 Feb; 23 Suppl 2():S214-21. PubMed ID: 25743330
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.
Riquelme I; Saavedra K; Espinoza JA; Weber H; García P; Nervi B; Garrido M; Corvalán AH; Roa JC; Bizama C
Oncotarget; 2015 Sep; 6(28):24750-79. PubMed ID: 26267324
[TBL] [Abstract][Full Text] [Related]
19. Review of recent molecular landscape knowledge of gastric cancer.
Shimizu D; Kanda M; Kodera Y
Histol Histopathol; 2018 Jan; 33(1):11-26. PubMed ID: 28447336
[TBL] [Abstract][Full Text] [Related]
20. Methylation-mediated gene silencing as biomarkers of gastric cancer: a review.
Nakamura J; Tanaka T; Kitajima Y; Noshiro H; Miyazaki K
World J Gastroenterol; 2014 Sep; 20(34):11991-2006. PubMed ID: 25232236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
